Secondary leukemia is a collective term used to describe a group of patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a history of environmental, occupational or therapeutic exposure to hematotoxins or radiation. Patients with AML evolving from antecedent myelodysplasia or other myeloid stem cell disorders, such as polycythemia vera or paroxysmal nocturnal hemoglobinuria, are included in this group. Therapy-related MDS or therapyrelated AML are also terms used to describe this syndrome, emphasizing important differences from AML that arises de novo. The term 'secondary leukemia' implies that the disease did not develop as a primary or de novo process. It should not be confused with leukemia that occurs as a second primary cancer. Response to therapy and prognosis are primarily determined by the cytogenetic findings. The clinical status of the patient with long-term MDS who now evolves to AML would also impact on the prognosis. It thus seems appropriate that secondary leukemias should be redefined as any leukemia with a specific cytogenetic or molecular poor prognostic feature, due to a presumed predisposing factor, rather than an emphasis on historical exposure.
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The most important group among the therapy-related leukemias is the one following therapy with alkylating agents which is usually associated with specific cytogenetic abnormalities in chromosomes 5 or 7.
3 An important group, although less frequent, are the leukemias following treatment with topoisomerase II inhibitors, usually characterized by the 11q abnormalities. Also, however, there is a small but important group of therapy-related leukemias following other miscellaneous therapies which may be characterized by other cytogenetic abnormalities including t(15;17), inv (16) Research Council in the UK. 5 In this report 119 patients had the so-called classic secondary leukemias and all received identical standard therapy. Interestingly, but not surprisingly, the response rate depended entirely on the cytogenetic group, very much as one would expect from any de novo AML.
The course and prognosis of secondary leukemias depend on clinical, cytogenetic and molecular features at diagnosis and, in this respect secondary leukemias are not fundamentally different from de novo AML. Secondary leukemias should probably not be considered as a separate entity although most secondary leukemias have unfavorable cytogenetics. Thus, secondary AML are synonymous with any AML that presents with unfavorable cytogenetics. It is preferable to base any definition on typical cytogenetic and molecular features and, pragmatically, for practical purposes and for lack of a better term, secondary leukemias should include any AML with poor prognostic features, whether or not they have a typical history. It is somewhat analogous to Philadelphia chromosome-positive myeloproliferative disorder, conventionally defined as Ph+ CML, whether or not accompanied by typical chronic myelogenous leukemia. Or, similarly, if one has classic molecular markers for paroxysmal nocturnal hemoglobinuria, one has PNH whether or not one has any of the clinical features. Although history is clearly important, it is the inclusive operational definition that is the key to prognosis and therapy.
Some superb work from the Southwestern Oncology Group (SWOG) in the USA demonstrated a very high frequency of multidrug resistance (MDR 1) among AML patients over 55 years, even among those considered as classically de novo. 6, 7 The common features among older patients with AML, who usually have unfavorable cytogenetics, and AML considered secondary to prior therapy are remarkably similar. Thus, more than 70% of patients had the MDRI expression which was highly predictable of resistant disease.
The historic literature on the treatment of secondary leukemias is striking for the absence of any prospective studies directly comparing results for this group of patients. Recommendations for therapy have often been intuitive and based on information from select phase II data. 8 Additionally, there remains a reluctance among many practicing physicians to enter such patients on clinical trials. There have been no phase III studies of induction or post-remission therapy of secondary leukemias and no evidence is available to suggest that any regimen is better than standard AML induction therapy consisting of an anthracycline and cytarabine (3 + 7), or similar. Although many regimens have been advocated for induction therapy of patients with secondary leukemias, the data from two recently published major prospective studies report a complete response rate of approximately 55% among AML patients with unfavorable cytogenetics, evaluated prospectively. 5, 9 None of the select reports of phase II patients suggest that any modification to standard induction therapy is better.
While patients with secondary leukemia can be expected to have an initial complete response rate of over 50%, most of them relapse and studies suggest that despite intensive postremission therapy only about 10% may be long-term survivors. 5, 9 Thus the ultimate challenge appears not in achieving an initial response; rather, in maintaining such a response and translating this into long-term survival. In this regard this is much like other acute leukemias with a very poor prognosis, such as Philadelphia chromosome-positive acute lymphocytic leukemia or AML in older adults. 10 Patients who achieve a complete remission should be offered intensive post-remission therapy if they are thought likely to tolerate such treatment. In younger adults, if an HLAmatched sibling donor is available, allogeneic BMT may be the preferred option, although there are no prospective data that absolutely establish this. While the US Intergroup Study suggested that 40-50% of such patients may be cured with allogeneic transplantation, 9 this advantage could not be confirmed in the MRC AML 10 trial. 5 However, in both studies very small cohorts of patients actually received this mode of therapy and so caution is appropriate in interpreting such data. A very recent report of the EORTC-GIMEMA AML 10 trial described a 4-year disease-free survival (DFS) of 44% for 63 patients with unfavorable cytogenetics who had a matched donor vs a DFS of only 19% for the 94 patients without a donor. 11 Retrospective registry analysis from the European Bone Marrow Transplant Group (EMBT) also suggests such a benefit for allogeneic transplant for this group of patients. 12 Thus, the current state-of-the-art, although based on scant prospective data, suggests that patients with secondary leukemia who have an HLA-matched sibling donor should be referred for allogeneic transplant as soon as possible. This is also based on reported data of a significant graft-versus-leukemia in this group of patients as judged by a reduced rate of leukemia relapse in most studies. In many of the published reports on allogeneic transplantation AML patients received at least one course of consolidation therapy. However, although prospective data are lacking, available information from the International Bone Marrow Transplant Registry suggests that there is no benefit in administering intensive consolidation therapy prior to undergoing an allogeneic transplant. 13 Such additional therapy may increase the overall toxicity leading to a delay in transplant, possible increase in transplant-related mortality and early relapse, without a demonstrated benefit in anti-leukemic efficacy. This consideration may be particularly pertinent in patients with secondary leukemia, among whom the risk of early relapse is very high.
The majority of patients cannot receive an HLA-matched sibling donor transplant either because they are too old for this or because they do not have a donor. For younger patients, if they are able to tolerate an allogeneic transplant, there may be a compelling rationale to offer them a transplant from an alternative donor. This is based on select phase II data from Seattle, indicating a long-term response rate of 40-50% in select patients receiving matched unrelated donors in first complete remission.
14 Similar data have been published from the University of Perugia, Italy, using haploidentical transplantation. 15 Whether these results can be safely reproduced in the relatively non-select setting of a cooperative group is the subject of a future clinical trial to be conducted by the Eastern Cooperative Oncology Group (ECOG) for AML patients with unfavorable cytogenetics who are in first complete remission.
It must be realized that allogeneic transplantation is currently an option for only a minority of patients with secondary leukemias. While the median age for all patients with AML is 64 years, it is significantly higher for patients who present with unfavorable cytogenetics. Therefore, only a small cohort of Leukemia such patients may ever be candidates for conventional allogeneic transplantation, even if they have a donor. Preliminary data suggest that newer methods using less severely myeloablative regimens and relying on the immunological effect of graft-versus-leukemia may yield almost comparable results and make this mode of therapy available to a significantly older cohort of patients. 16 However, such preliminary data also need to be confirmed in prospective clinical trials.
For patients who are not candidates for any form of allogeneic transplantation a difficult dilemma exists as to the most appropriate post-remission therapy. Despite poor long-term results it would seem appropriate to offer younger individuals conventional intensive post-remission therapy. While uncertainty remains as to the best such treatment, 17 high-dose cytarabine is probably a reasonable choice with subsequent autologous stem cell transplantation. Among older adults, who are unable to withstand the rigors of intensive chemotherapy experimental approaches using immunotherapeutic manipulations such as IL2/histamine, IL2 alone, flt3 ligand, targeted therapies such as gemtuzumab ozogamicin or farnesyltranesferase inhibitors need to be considered.
Other studies include biologic response modifiers such as the bcl-2 antisense oligonucleotides or modifiers of the flt3 ligand tandem duplications. This remains an unsatisfactory area with the greatest clinical challenge in AML; applying a less severely myeloablative regimen of post-remission therapy that may, nevertheless, cure the most unfavorable prognostic types of AML. Achieving this aim has so far been illusive. Such breakthroughs, if they occur, will likely also benefit younger adults.
